These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12362366)

  • 21. New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor.
    Macchia M; Cervetto L; Demontis GC; Longoni B; Minutolo F; Orlandini E; Ortore G; Papi C; Sbrana A; Macchia B
    J Med Chem; 2003 Jan; 46(1):161-8. PubMed ID: 12502370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands.
    Sasse BC; Mach UR; Leppaenen J; Calmels T; Stark H
    Bioorg Med Chem; 2007 Dec; 15(23):7258-73. PubMed ID: 17826096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.
    Pruitt JR; Batt DG; Wacker DA; Bostrom LL; Booker SK; McLaughlin E; Houghton GC; Varnes JG; Christ DD; Covington M; Das AM; Davies P; Graden D; Kariv I; Orlovsky Y; Stowell NC; Vaddi KG; Wadman EA; Welch PK; Yeleswaram S; Solomon KA; Newton RC; Decicco CP; Carter PH; Ko SS
    Bioorg Med Chem Lett; 2007 Jun; 17(11):2992-7. PubMed ID: 17418570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179).
    Einsiedel J; Hübner H; Gmeiner P
    Bioorg Med Chem Lett; 2001 Sep; 11(18):2533-6. PubMed ID: 11549463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indolylpiperidine derivatives as potent and selective α1B adrenoceptor antagonists.
    Hayashi R; Ohmori E; Moriwaki M; Kumagai H; Isogaya M
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3921-3. PubMed ID: 26238322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymmetric synthesis of chiral piperazinylpropylisoxazoline ligands for dopamine receptors.
    Jung JY; Jung SH; Koh HY
    Eur J Med Chem; 2007 Jul; 42(7):1044-8. PubMed ID: 17316913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydrazides of clozapine: a new class of D1 dopamine receptor subtype selective antagonists.
    Sasikumar TK; Burnett DA; Zhang H; Smith-Torhan A; Fawzi A; Lachowicz JE
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4543-7. PubMed ID: 16809034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-168077, a selective dopamine D4 receptor agonist, induces penile erection when injected into the paraventricular nucleus of male rats.
    Melis MR; Succu S; Mascia MS; Argiolas A
    Neurosci Lett; 2005 Apr; 379(1):59-62. PubMed ID: 15814200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), alpha1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics.
    Bojarski AJ; Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
    Bioorg Med Chem; 2005 Mar; 13(6):2293-303. PubMed ID: 15727878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species.
    Lyles-Eggleston M; Altundas R; Xia J; Sikazwe DM; Fan P; Yang Q; Li S; Zhang W; Zhu X; Schmidt AW; Vanase-Frawley M; Shrihkande A; Villalobos A; Borne RF; Ablordeppey SY
    J Med Chem; 2004 Jan; 47(3):497-508. PubMed ID: 14736232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists.
    Alker A; Binggeli A; Christ AD; Green L; Maerki HP; Martin RE; Mohr P
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4521-5. PubMed ID: 20580234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.
    Dutta AK; Venkataraman SK; Fei XS; Kolhatkar R; Zhang S; Reith ME
    Bioorg Med Chem; 2004 Aug; 12(16):4361-73. PubMed ID: 15265488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.
    Gyertyán I; Kiss B; Gál K; Laszlovszky I; Horváth A; Gémesi LI; Sághy K; Pásztor G; Zájer M; Kapás M; Csongor EA; Domány G; Tihanyi K; Szombathelyi Z
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1268-78. PubMed ID: 17170312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
    Nakane M; Cowart MD; Hsieh GC; Miller L; Uchic ME; Chang R; Terranova MA; Donnelly-Roberts DL; Namovic MT; Miller TR; Wetter JM; Marsh K; Stewart AO; Brioni JD; Moreland RB
    Neuropharmacology; 2005 Jul; 49(1):112-21. PubMed ID: 15992586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5).
    Moreland RB; Nakane M; Donnelly-Roberts DL; Miller LN; Chang R; Uchic ME; Terranova MA; Gubbins EJ; Helfrich RJ; Namovic MT; El-Kouhen OF; Masters JN; Brioni JD
    Biochem Pharmacol; 2004 Aug; 68(4):761-72. PubMed ID: 15276084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands.
    Ji M; Chen J; Ding K; Wu X; Varady J; Levant B; Wang S
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1701-5. PubMed ID: 15745825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands.
    Ding K; Chen J; Ji M; Wu X; Varady J; Yang CY; Lu Y; Deschamps JR; Levant B; Wang S
    J Med Chem; 2005 May; 48(9):3171-81. PubMed ID: 15857123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
    J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.